In vitro sensitivity to methyl-prednisolone for predicting clinical response in pediatric idiopathic nephrotic syndrome

E. Cuzzoni¹, A. Pasini², S. De Iudicibus³, G. Stocco⁴, D. Favretto⁴, M. Pelin⁴, G. Decorti⁴, C. La Scola², E. Monti⁴, A. Edefonti⁵, L. Ghio³, E. Groppadi⁵, C. Malaventura⁶, G. Messina⁶, F. Pugliese⁸, G. Montini², e il gruppo Nefrokid

¹PhD School in Sciences of Reproduction and Development, University of Trieste, Trieste, Italy
²Nephrology and Pediatric Dialysis, Dept. of Pediatrics, Azienda Ospedaliera Universitaria Sant'Orsola, Bologna, Italy
³Institute for Maternal and Child Health IRCCS Burlo Garofolo, Trieste, Italy
⁴Dept. of Life Sciences, University of Trieste, Trieste, Italy
⁵Ospedale Maggiore Policlinico Milano, Division of Pediatric Nephology and Kidney Transplantation, Milan, Italy
⁶University of Ferrara, Dept. of Medical Sciences, Ferrara, Italy
⁷Children's Hospital Giovanni XXIII, Nephrology Unit, Bari, Italy
⁸Ospedale di Ravenna, Ravenna, Italy

The response to glucocorticoid (GC) treatment is an important indicator of the outcome of idiopathic nephrotic syndrome (INS) as patients with poor response have unfavorable prognosis. The inhibition of proliferation of peripheral blood mononuclear cells (PBMC) by GCs has been correlated with clinical response in various diseases. The aim of this study was to evaluate the in vitro anti-proliferative activity of GCs as predictor of steroid response in pediatric INS children.

As part of a prospective multicenter study of steroid treatment at onset of pediatric INS, the in vitro inhibition of PBMC proliferation by [methyl-H³]-thymidine incorporation was evaluated before (T0) and after 4 weeks (T4) of steroid treatment in 74 patients (median age 4.33, IQR IQR 2.82-7.23; 63.5% male). The drug concentration that induced 50% of growth inhibition (IC₅₀) and the maximum inhibition achievable at the highest drug concentration (Iₘₐₓ) were determined. Receiver operating characteristics (ROC) curves identified optimal cut-off points to predict clinical response. Children were treated with a shared protocol as regards steroid and symptomatic treatment of the INS.

At T0, univariate analysis showed an association between GC-resistance and reduced in vitro methyl-prednisolone response evaluated as Iₘₐₓ (OR=1.07, 95% CI=1.00-1.15; p-value= 0.046). At T4, a significant association between clinical dependence to GCs and increased in vitro response was observed both for Iₘₐₓ (OR=1.13, 95% CI=1.02-1.31; p-value=0.017) and IC₅₀ (OR=0.48, 95% CI=0.24–0.85; p-value=0.0094). Optimal predictor of clinical dependence evaluated by ROC curves, was Iₘₐₓ at T4 ≥ 92%. Moreover an association between age at the onset of the disease and Iₘₐₓ (p-value=0.043, r=-0.25) and clinical response (OR = 0.81, 95% CI=0.67-0.98; p-value=0.028) was found.

These results suggest that the in vitro proliferation test may be useful in the prediction of response to GCs in pediatric patients with INS.